← Back to all trials
Completed
NCT07644351
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients
Conditions: Acute Lymphoblastic Leukemia
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 37
Sponsor: Novartis Pharmaceuticals
Location: Novartis Investigative Site Boston Massachusetts
Summary
The aim of this study was to collect existing information from the medical charts of patients enrolled in the ongoing asciminib Managed Access Program (MAP) to better understand the effectiveness and safety of asciminib when used to treat adult patients with Ph+ ALL who are refractory, resistant or intolerant to available treatments.
Eligibility Criteria
Inclusion criteria
* Adult patients enrolled in the asciminib MAP.
* Diagnosis of Ph+ ALL.
* Patients received at least one dose of asciminib through the asciminib MAP.
* Appropriate approval obtained for the use of patient data including:
* Signed informed consent form (ICF), or
* ICF waiver granted by an Institutional review board/Independent Ethics Committee (IRB/IEC).
Exclusion criteria
• Age \< 18 years at the time of initiating asciminib treatment.
Source: ClinicalTrials.gov (NCT07644351). StuddyBuddy aggregates publicly available trial information.
